Tian Zhang, MD

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III randomized KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC).

This study is currently in progress, and started accruing patients earlier this year. The primary endpoint of the study is disease-free survival. Investigators are aiming to enroll high-risk patients with high-risk features. As there are currently no standard of care treatments in the adjuvant setting of kidney cancer, this study, as well as several other ongoing studies, aim to improve adjuvant treatment for these patients, Zhang says. &nbsp;

Videos

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC).&nbsp;<br />
&nbsp;

Tian Zhang, MD | Authors

Articles

A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma